Summary Report of PQRI Workshop on Nanomaterial in Drug Products: Current Experience and Management of Potential Risks
暂无分享,去创建一个
Celia N. Cruz | M. Brewster | R. Prud’homme | N. Sadrieh | D. Cabral-Lilly | L. Tamarkin | C. Sayes | W. Zamboni | A. Jacobs | R. Nalubola | K. Tyner | F. Malinoski | W. Eickhoff | J. Bartlett | Paul C. Brown | Raymond David | Sabine Haubenreisser | E. Morefield | Hripsime Shahbazian | N. Subbarao | Rajendra Uppoor | Margaret Whittaker-Caulk | J. A. Bartlett | M. Brewster | Lawrence Tamarkin
[1] Matthew Howard,et al. Best Practices for the Development, Scale-up, and Post-approval Change Control of IR and MR Dosage Forms in the Current Quality-by-Design Paradigm , 2014, AAPS PharmSciTech.
[2] C. Sayes. The Relationships among Structure, Activity, and Toxicity of Engineered Nanoparticles , 2014 .
[3] M. Walsh,et al. Meta-analysis of inter-patient pharmacokinetic variability of liposomal and non-liposomal anticancer agents. , 2014, Nanomedicine : nanotechnology, biology, and medicine.
[4] Haibo Zhou,et al. Translational Studies of Phenotypic Probes for the Mononuclear Phagocyte System and Liposomal Pharmacology , 2013, The Journal of Pharmacology and Experimental Therapeutics.
[5] Rong-Kun Chang,et al. Pharmaceutical development and regulatory considerations for nanoparticles and nanoparticulate drug delivery systems. , 2013, Journal of pharmaceutical sciences.
[6] Jan P Möschwitzer,et al. Drug nanocrystals in the commercial pharmaceutical development process. , 2013, International journal of pharmaceutics.
[7] R. Duncan,et al. Next-generation nanomedicines and nanosimilars: EU regulators' initiatives relating to the development and evaluation of nanomedicines. , 2013, Nanomedicine.
[8] Celia N. Cruz,et al. CDER Risk Assessment Exercise to Evaluate Potential Risks from the Use of Nanomaterials in Drug Products , 2013, The AAPS Journal.
[9] Sokindra Kumar,et al. Nanoparticles-mediated drug delivery approaches for cancer targeting: a review , 2013, Journal of drug targeting.
[10] Marina A. Dobrovolskaia,et al. Common pitfalls in nanotechnology: lessons learned from NCI's Nanotechnology Characterization Laboratory. , 2013, Integrative biology : quantitative biosciences from nano to macro.
[11] H. Maeda,et al. The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. , 2013, Advanced drug delivery reviews.
[12] Fang Wang,et al. Application of Drug Nanocrystal Technologies on Oral Drug Delivery of Poorly Soluble Drugs , 2012, Pharmaceutical Research.
[13] V. Bae-Jump,et al. 126 Relationship Between Complement Factors and CC Chemokines and the Pharmacokinetics (PK) and Pharmacodynamics (PD) of PEGylated Liposomal Doxorubicin (PLD) in Patients with Refractory Epithelial Ovarian Cancer (EOC) , 2012 .
[14] Y. Bang,et al. Mechanism-based model characterizing bidirectional interaction between PEGylated liposomal CKD-602 (S-CKD602) and monocytes in cancer patients , 2012, International journal of nanomedicine.
[15] T. Ishida,et al. Accelerated blood clearance of PEGylated liposomes containing doxorubicin upon repeated administration to dogs. , 2012, International journal of pharmaceutics.
[16] T. Andresen,et al. Particulate Systems for Targeting of Macrophages: Basic and Therapeutic Concepts , 2012, Journal of Innate Immunity.
[17] Vladimir Torchilin,et al. Best Practices in Cancer Nanotechnology: Perspective from NCI Nanotechnology Alliance , 2012, Clinical Cancer Research.
[18] W. Zamboni,et al. Interpatient Pharmacokinetic and Pharmacodynamic Variability of Carrier‐Mediated Anticancer Agents , 2012, Clinical pharmacology and therapeutics.
[19] V. Bae-Jump,et al. Abstract 2673: Relationship between serum hormone levels and pharmacokinetics (PK) of PEGylated liposomal doxorubicin (PLD) in patients with refractory ovarian cancer , 2012 .
[20] D. Kingston,et al. Conformationally constrained and nanoparticle-targeted paclitaxels , 2012, Pure and applied chemistry. Chimie pure et appliquee.
[21] H. Nasrallah,et al. Clinical pharmacology of paliperidone palmitate a parenteral long-acting formulation for the treatment of schizophrenia. , 2012, Reviews on recent clinical trials.
[22] G. Van den Mooter,et al. Bead layering as a process to stabilize nanosuspensions: influence of drug hydrophobicity on nanocrystal reagglomeration following in‐vitro release from sugar beads , 2011, The Journal of pharmacy and pharmacology.
[23] R. Duncan,et al. Nanomedicine(s) under the microscope. , 2011, Molecular pharmaceutics.
[24] Suzanne M D'Addio,et al. Controlling drug nanoparticle formation by rapid precipitation. , 2011, Advanced drug delivery reviews.
[25] Elaine Merisko-Liversidge,et al. Nanosizing for oral and parenteral drug delivery: a perspective on formulating poorly-water soluble compounds using wet media milling technology. , 2011, Advanced drug delivery reviews.
[26] S. Ramalingam,et al. Bidirectional pharmacodynamic interaction between pegylated liposomal CKD-602 (S-CKD602) and monocytes in patients with refractory solid tumors , 2011, Journal of liposome research.
[27] Rainer H Müller,et al. State of the art of nanocrystals--special features, production, nanotoxicology aspects and intracellular delivery. , 2011, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[28] Jinming Gao,et al. Nanonization strategies for poorly water-soluble drugs. , 2011, Drug discovery today.
[29] J. Kolitz,et al. First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] Kenneth A. Dawson,et al. Nanobiotechnology: Nanoparticle coronas take shape , 2011 .
[31] M. Dobrovolskaia,et al. In vitro analysis of nanoparticle uptake by macrophages using chemiluminescence. , 2011, Methods in molecular biology.
[32] A. Gabizon,et al. Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients , 2011, Cancer Chemotherapy and Pharmacology.
[33] G. Kulkarni,et al. Optimization of formulation and process variable of nanosuspension: An industrial perspective. , 2010, International journal of pharmaceutics.
[34] Jouni Hirvonen,et al. Pharmaceutical nanocrystals by nanomilling: critical process parameters, particle fracturing and stabilization methods , 2010, The Journal of pharmacy and pharmacology.
[35] Ranjita Shegokar,et al. Nanocrystals: industrially feasible multifunctional formulation technology for poorly soluble actives. , 2010, International journal of pharmaceutics.
[36] Lawrence Tamarkin,et al. Phase I and Pharmacokinetic Studies of CYT-6091, a Novel PEGylated Colloidal Gold-rhTNF Nanomedicine , 2010, Clinical Cancer Research.
[37] S. Barni,et al. Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel , 2010, Expert opinion on pharmacotherapy.
[38] W. Zamboni,et al. DDS製品開発の最前線 Formulation and physiological factors affecting the pharmacokinetics and pharmacodynamics of liposomal anticancer agents , 2010 .
[39] S. Ramalingam,et al. Pharmacokinetic Study of Pegylated Liposomal CKD‐602 (S‐CKD602) in Patients With Advanced Malignancies , 2009, Clinical pharmacology and therapeutics.
[40] Nakissa Sadrieh,et al. Regulatory perspective on the importance of ADME assessment of nanoscale material containing drugs. , 2009, Advanced drug delivery reviews.
[41] Kenneth A. Dawson,et al. Nanotoxicology: nanoparticles reconstruct lipids. , 2009, Nature nanotechnology.
[42] Eric Pridgen,et al. Factors Affecting the Clearance and Biodistribution of Polymeric Nanoparticles , 2008, Molecular pharmaceutics.
[43] Carmen Popescu,et al. Conversion of Nanosuspensions into Dry Powders by Spray Drying: A Case Study , 2008, Pharmaceutical Research.
[44] L. Mayer,et al. Intra and Inter-Molecular Interactions Dictate the Aggregation State of Irinotecan Co-Encapsulated with Floxuridine Inside Liposomes , 2008, Pharmaceutical Research.
[45] Ben J Boyd,et al. Past and future evolution in colloidal drug delivery systems , 2008, Expert opinion on drug delivery.
[46] H. Shmeeda,et al. An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicin , 2008, Cancer Chemotherapy and Pharmacology.
[47] Filippos Kesisoglou,et al. Nanosizing--oral formulation development and biopharmaceutical evaluation. , 2007, Advanced drug delivery reviews.
[48] M. Dobrovolskaia,et al. Immunological properties of engineered nanomaterials , 2007, Nature Nanotechnology.
[49] David B Warheit,et al. Assessing toxicity of fine and nanoparticles: comparing in vitro measurements to in vivo pulmonary toxicity profiles. , 2007, Toxicological sciences : an official journal of the Society of Toxicology.
[50] Rebekah Drezek,et al. Forming biocompatible and nonaggregated nanocrystals in water using amphiphilic polymers. , 2007, Journal of the American Chemical Society.
[51] Jean-Pierre Benoit,et al. Parameters influencing the stealthiness of colloidal drug delivery systems. , 2006, Biomaterials.
[52] Nicholas A Peppas,et al. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. , 2006, International journal of pharmaceutics.
[53] C. Benz,et al. Future directions of liposome- and immunoliposome-based cancer therapeutics. , 2004, Seminars in oncology.
[54] Cornelia M Keck,et al. Challenges and solutions for the delivery of biotech drugs--a review of drug nanocrystal technology and lipid nanoparticles. , 2004, Journal of biotechnology.
[55] J. West,et al. The Differential Cytotoxicity of Water-Soluble Fullerenes , 2004 .
[56] Lawrence Tamarkin,et al. Colloidal Gold: A Novel Nanoparticle Vector for Tumor Directed Drug Delivery , 2004, Drug delivery.
[57] Theresa M Allen,et al. Multiple Injections of Pegylated Liposomal Doxorubicin: Pharmacokinetics and Therapeutic Activity , 2003, Journal of Pharmacology and Experimental Therapeutics.
[58] Sung-Wook Choi,et al. Surface Modification of Functional Nanoparticles for Controlled Drug Delivery , 2003 .
[59] R. Gurny,et al. Biodegradable nanoparticles — From sustained release formulations to improved site specific drug delivery , 1996 .
[60] G. Liversidge,et al. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs , 1995 .
[61] R. Juliano,et al. Pharmacokinetics of liposome-encapsulated anti-tumor drugs. Studies with vinblastine, actinomycin D, cytosine arabinoside, and daunomycin. , 1978, Biochemical pharmacology.
[62] G. Birrenbach,et al. Polymerized micelles and their use as adjuvants in immunology. , 1976, Journal of pharmaceutical sciences.
[63] G Gregoriadis,et al. Drug entrapment in liposomes , 1973, FEBS letters.
[64] K. Shadan,et al. Available online: , 2012 .